Potent dual BET bromodomain-kinase inhibitors as value added multi-targeted chemical probes and cancer therapeutics

Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers. Using the chemical scaffold of the JAK2 inhibitor TG101348 we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Ember, Stuart W., Lambert, Que T., Berndt, Norbert, Gunawan, Steven, Ayaz, Muhammad, Tauro, Marilena, Zhu, Jin-Yi, Cranfill, Paula J., Greninger, Patricia, Lynch, Conor C., Benes, Cyril H., Lawrence, Harshani R., Reuther, Gary W., Lawrence, Nicholas J., Schönbrunn, Ernst
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457702/
https://ncbi.nlm.nih.gov/pubmed/28336808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0568-T
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars